
Mounzer E Agha MD
Hematologic Oncology
Director, Mario Lemieux Center for Blood Cancers
Join to view full profile
5115 Centre Ave3rd FloorPittsburgh, PA 15232
Phone+1 412-864-6648
Fax+1 412-864-6666
Dr. Agha is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1992
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 1986 - 1989
University of Aleppo Faculty of MedicineClass of 1983
Certifications & Licensure
PA State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2015-2016
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2015-2016
Clinical Trials
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Publications & Presentations
PubMed
- 1 citationsSystematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia.Mounzer E Agha, Sarah McGregor, Kevin C De Braganca, Tamar Lengil, Victoria Alegria
Cancer Treatment and Research Communications. 2026-01-01 - 1 citationsAllogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.Celalettin Ustun, Mei-Jie Zhang, Andrew Peterson, Alexander Baek, Mounzer Agha
British Journal of Haematology. 2025-12-01 - 53 citationsLong-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje
Journal of Clinical Oncology. 2025-09-01
Authored Content
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021
Press Mentions
Who Qualifies for a Coronavirus Booster Shot? Why It’s Still UnclearAugust 13th, 2021
Protecting the Immune-Compromised Keeps Everyone SafeAugust 5th, 2021
The Complex Situation for Immunocompromised People and COVID-19 VaccinesJune 16th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









